Ghanem Heba A, Nasr Ali M, Hassan Tamer H, Elkhoudary Mahmoud M, Alshaman Reem, Alattar Abdullah, Gad Shadeed
Department of Pharmaceutics, Faculty of Pharmacy, Sinai University, Al Qantarah Sharq 41636, Egypt.
Department of Pharmaceutics, Faculty of Pharmacy, Port Said University, Port Said 42526, Egypt.
Pharmaceutics. 2021 Jan 28;13(2):178. doi: 10.3390/pharmaceutics13020178.
The aim of the current study is to establish a comprehensive experimental design for the screening and optimization of Atorvastatin-loaded nanostructured lipid carriers (AT-NLCs). Initially, combined D-optimal screening design was applied to find the most significant factors affecting AT-NLCs properties. The studied variables included mixtures of solid and liquid lipids, the solid/liquid lipid ratio, surfactant type and concentration, homogenization speed as well as sonication time. Then, the variables homogenization speed (A), the ratio of solid lipid/liquid lipid (B), and concentration of the surfactant (C) were optimized using a central composite design. Particle size, polydispersity index, zeta potential, and entrapment efficiency were chosen as dependent responses. The optimized AT-NLCs demonstrated a nanometric size (83.80 ± 1.13 nm), Polydispersity Index (0.38 ± 0.02), surface charge (-29.65 ± 0.65 mV), and high drug incorporation (93.1 ± 0.04%). Fourier Transform Infrared Spectroscopy (FTIR) analysis showed no chemical interaction between Atorvastatin and the lipid mixture. Differential Scanning Calorimetry (DSC) analysis of the AT-NLCs suggested the transformation of Atorvastatin crystal into an amorphous state. Administration of the optimized AT-NLCs led to a significant reduction ( < 0.001) in serum levels of rats' total cholesterol, triglycerides, and low-density lipoproteins. This change was histologically validated by reducing the relevant steatosis of the liver.
本研究的目的是建立一种全面的实验设计,用于筛选和优化载有阿托伐他汀的纳米结构脂质载体(AT-NLCs)。最初,采用组合D-最优筛选设计来找出影响AT-NLCs性质的最显著因素。所研究的变量包括固体和液体脂质的混合物、固/液脂质比、表面活性剂类型和浓度、均质速度以及超声处理时间。然后,使用中心复合设计对变量均质速度(A)、固体脂质/液体脂质比(B)和表面活性剂浓度(C)进行优化。选择粒径、多分散指数、zeta电位和包封率作为相关响应指标。优化后的AT-NLCs呈现出纳米尺寸(83.80±1.13 nm)、多分散指数(0.38±0.02)、表面电荷(-29.65±0.65 mV)以及较高的药物包封率(93.1±0.04%)。傅里叶变换红外光谱(FTIR)分析表明阿托伐他汀与脂质混合物之间不存在化学相互作用。对AT-NLCs的差示扫描量热法(DSC)分析表明阿托伐他汀晶体转变为无定形状态。给予优化后的AT-NLCs可使大鼠血清中总胆固醇、甘油三酯和低密度脂蛋白水平显著降低(<0.001)。通过减轻肝脏相关脂肪变性在组织学上验证了这一变化。